title: The experience is CLEAR.
abstract: Conventional amphotericin B has been the 'gold standard' for antifungal efficacy, but nephrotoxicity problems limit its clinical utility. In the late 1990s, three lipid-based formulations of amphotericin B were introduced, all of which offered comparable efficacy and reduced renal complications. However, to date, robust safety and comparative efficacy data have been sparse. This paper briefly reviews the available clinical data on amphotericin B lipid complex (ABLC). Also, in detail, it reviews the findings of Collaborative Exchange of Antifungal Research (CLEAR), the most extensive dataset on systemic antifungal treatment with the lipid-based agent ABLC.
authors.affiliation: Division of Infectious Diseases, Wayne State University School of Medicine, Harper Hospital, Detroit, MI, USA. pchandrasekar@med.wayne.edu
authors.forename: Pranatharthi
authors.initials: P
authors.lastname: Chandrasekar
mesh_terms: D000666:Amphotericin B / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003453:Cryptococcosis / Q000175:diagnosis / Q000188:drug therapy; D016208:Databases, Factual; D004338:Drug Combinations; D006801:Humans; D066298:In Vitro Techniques; D015337:Multicenter Studies as Topic; D009181:Mycoses / Q000175:diagnosis / Q000188:drug therapy*; D010713:Phosphatidylcholines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010715:Phosphatidylglycerols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011446:Prospective Studies; D016896:Treatment Outcome; D020096:Zygomycosis / Q000175:diagnosis / Q000188:drug therapy
chemical_list: D000935:Antifungal Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B